Dr. Daniel J. Ladd JR., DO
Dermatology (Procedural Dermatology Physician)
At a glance
- Medical school
- Des Moines University of Osteopathic Medicine and Health Sciences (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2005
Licensed in Texas since 2000, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Des Moines University of Osteopathic Medicine and Health Sciences
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Procedural Dermatology Physician primary
TX license L1102 (first issued 2000; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Pinnacle Dermatology Sc (148 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Pathology examination of tissue using a microscope, intermediate complexity | 4,088 | 1,700 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 13 companies reported 21 payments worth $419 in total to this clinician.
| Amgen Inc. | $65.20 |
|---|---|
| AbbVie Inc. | $55.72 |
| Janssen Biotech, Inc. | $44.52 |
| Arcutis Biotherapeutics, Inc. | $43.03 |
| Boston Scientific Corporation | $38.53 |
| Kerecis Limited | $30.54 |
| Mayne Pharma Commercial LLC | $23.71 |
| Regeneron Healthcare Solutions, Inc. | $22.03 |
| Food and Beverage | $419 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.